KYUNG NAM PHARM.CO.,LTD. Q3 revenue KRW 20.7 billion, operating loss KRW 1.3 billion
AI summary · Not investment advice
Kyungnam Pharm sold KRW 20.7 billion in Q3 and lost KRW 1.3 billion from its main business; sales rose 46.2% from a year earlier and 16.3% from the prior quarter.
Operating profit · 3 months
KRW -1.3 billion
Key facts
- Revenue (3 months)
- KRW 20.7 billion
- Net income (3 months)
- KRW -2.9 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 14.2 billion
- Revenue (year to date)
- KRW 54.6 billion
- Operating profit (prior-year 3 months)
- KRW -1.1 billion
- Operating profit (year to date)
- KRW -1.1 billion
- Net income (prior-year 3 months)
- KRW -4.7 billion
- Net income (year to date)
- KRW -7.2 billion
Commentary
AI commentary · Not investment advice
What happened
Kyungnam Pharm reported its consolidated results for the third quarter of 2026. Sales for the quarter were KRW 20.71 billion. That is 46.2% more than the same 3 months a year earlier (KRW 14.16 billion) and 16.3% more than the previous quarter.
In the company's terms
Operating profit (profit from the core business) was a loss of KRW 1.31 billion for the quarter. A year earlier, the same 3 months showed a loss of KRW 1.06 billion. Net income was a loss of KRW 2.89 billion, compared with a loss of KRW 4.68 billion a year earlier.
What changes for shareholders
For the year to date (Jan 1 to Sep 30, 2026), sales were KRW 54.65 billion. Operating profit was a loss of KRW 1.14 billion. Net income was a loss of KRW 7.15 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
K